IL18 and neoplasm: The application of dendritic cells producing IL-12 only resulted in a statistically significant TGI of MC38 tumors amounted to 65.77%, whereas the use in the therapy of dendritic cells producing IL-12 and IL-18 simultaneously resulted in increase in tumor growth inhibition to 70.25%.